Optimal influenza vaccine distribution with equity

Enayati, Shakiba; Özaltın, Osman Y.

doi:10.1016/j.ejor.2019.11.025

Cited by 134 publications

(104 citation statements)

References 57 publications

Supporting

Mentioning

104

Contrasting

Order By: Relevance

“…These articles broadly focus on two major areas: (1) allocating resources to increase supply chain capabilities during large-scale disruptions; and (2) redesigning logistics and supply chain networks to reduce vulnerability. In the first area, articles have highlighted resource shortages as a major obstacle during an epidemic ( Enayati and Özaltın, 2020 , Liu et al, 2020 , Parvin et al, 2018 , Rachaniotis et al, 2012 , Savachkin and Uribe, 2012 , Sun et al, 2014 ). Consequently, these studies offered various strategies for allocating minimal or further resources, such as controlling transportation costs and equitable policies ( Savachkin and Uribe, 2012 ); undertaking threshold policy for inventory balancing; optimal area-based trans-shipment policy and planning horizon ( Parvin et al, 2018 ); increasing capacity to manage disruptions ( Hessel, 2009 , Sun et al, 2014 ); implementing cost-sharing contracts ( Mamani et al, 2013 ) or coordinating contracts ( Chick et al, 2008 ); and appropriate capacity setting and the minimum budget ( Liu et al, 2020 ).…”

Section: Review On Prior Epidemic Outbreaks and Disruptions In Supplymentioning

confidence: 99%

COVID-19 pandemic related supply chain studies: A systematic review

Chowdhury

Paul

Kaisar

et al. 2021

Transportation Research Part E: Logistics and Transportation Re

690

548

View full text Add to dashboard Cite

The global spread of the novel coronavirus, also known as the COVID-19 pandemic, has had a devastating impact on supply chains. Since the pandemic started, scholars have been researching and publishing their studies on the various supply-chain-related issues raised by COVID-19. However, while the number of articles on this subject has been steadily increasing, due to the absence of any systematic literature reviews, it remains unclear what aspects of this disruption have already been studied and what aspects still need to be investigated. The present study systematically reviews existing research on the COVID-19 pandemic in supply chain disciplines. Through a rigorous and systematic search, we identify 74 relevant articles published on or before 28 September 2020. The synthesis of the findings reveals that four broad themes recur in the published work: namely, impacts of the COVID-19 pandemic, resilience strategies for managing impacts and recovery, the role of technology in implementing resilience strategies, and supply chain sustainability in the light of the pandemic. Alongside the synthesis of the findings, this study describes the methodologies, context, and theories used in each piece of research. Our analysis reveals that there is a lack of empirically designed and theoretically grounded studies in this area; hence, the generalizability of the findings, thus far, is limited. Moreover, the analysis reveals that most studies have focused on supply chains for high-demand essential goods and healthcare products, while low-demand items and SMEs have been largely ignored. We also review the literature on prior epidemic outbreaks and other disruptions in supply chain disciplines. By considering the findings of these articles alongside research on the COVID-19 pandemic, this study offers research questions and directions for further investigation. These directions can guide scholars in designing and conducting impactful research in the field.

show abstract

Section: Review On Prior Epidemic Outbreaks and Disruptions In Supplymentioning

confidence: 99%

COVID-19 pandemic related supply chain studies: A systematic review

Chowdhury

Paul

Kaisar

et al. 2021

Transportation Research Part E: Logistics and Transportation Re

690

548

View full text Add to dashboard Cite

show abstract

“…They used a fuzzy goal programming approach to solve and validate their model with data collected from Iran’s Avonex distribution chain. Enayati and Özaltın [22] introduced a mathematical programming model for equitable influenza vaccine distribution in a heterogeneous population. Their model minimizes the vaccine doses allocated to subgroups for preventing the disease outbreak at the early stages of the epidemic.…”

Section: Introductionmentioning

confidence: 99%

“…This study proposes a mathematical model for equitable influenza vaccine distribution, similar to Enayati and Özaltın [22] . However, we go one step further and introduce a new concept for equitable vaccine distribution using a customizable objective function applicable to the COVID-19 vaccine.…”

Section: Introductionmentioning

confidence: 99%

“…However, we go one step further and introduce a new concept for equitable vaccine distribution using a customizable objective function applicable to the COVID-19 vaccine. In addition, unlike the Enayati and Özaltın’s [22] model, we consider the location of distribution centers and storage facilities, vaccine shortage, and budget constraints in the proposed model. In summary, this study addresses the following questions: How can an optimization model address the need for an equitable influenza vaccine distribution to a heterogeneous population?…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

An inventory-location optimization model for equitable influenza vaccine distribution in developing countries during the COVID-19 pandemic

Rastegar

Tavana

Meraj

et al. 2021

Vaccine

106

View full text Add to dashboard Cite

“…The epidemiology literature previously recognized the possibility that the nonlinear nature of epidemics may dictate optimal policy concentrating a scarce stockpile in one population rather spreading across them. Keeling and Shattock (2012) provided an early contribution, subsequently refined by work including Keeling and Ross (2015), Nguyen and Carlson (2016), and Enayati and 'Ozaltin (2020). This literature has the advantage of studying increasingly rich epidemiological models, the results are simulated in numerical examples.…”

Section: Introductionmentioning

confidence: 99%

Optimal Vaccine Subsidies for Endemic and Epidemic Diseases

Goodkin-Gold

Kremer

Snyder

et al. 2020

View full text Add to dashboard Cite

Vaccines exert a positive externality, reducing spread of disease from the consumer to others, providing a rationale for subsidies. We study how optimal subsidies vary with disease characteristics by integrating a standard epidemiological model into a vaccine market with rational economic agents. In the steady-state equilibrium for an endemic disease, across market structures ranging from competition to monopoly, the marginal externality and optimal subsidy are non-monotonic in disease infectiousness, peaking for diseases that spread quickly but not so quickly as to drive all consumers to become vaccinated.Motivated by the Covid-19 pandemic, we adapt the analysis to study a vaccine campaign introduced at a point in time against an emerging epidemic. While the nonmonotonic pattern of the optimal subsidy persists, new findings emerge. Universal vaccination with a perfectly effective vaccine becomes a viable firm strategy: the marginal consumer is still willing to pay since those infected before vaccine rollout remain a source of transmission. We derive a simple condition under which vaccination exhibits increasing social returns, providing an argument for concentrating a capacity-constrained campaign in few regions. We discuss a variety of extensions and calibrations of the results to vaccines and other mitigation measures targeting existing diseases.

show abstract

Optimal influenza vaccine distribution with equity

Cited by 134 publications

References 57 publications

COVID-19 pandemic related supply chain studies: A systematic review

COVID-19 pandemic related supply chain studies: A systematic review

An inventory-location optimization model for equitable influenza vaccine distribution in developing countries during the COVID-19 pandemic

Optimal Vaccine Subsidies for Endemic and Epidemic Diseases

Contact Info

Product

Resources

About